$RCEL
AVITA Medical, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023062024 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $14.20M $13.65M
YoY Change 50.13% 50.08%
Cost Of Revenue $1.796M $2.113M
YoY Change 42.99% 38.1%
Gross Profit $12.40M $11.53M
YoY Change 51.23% 52.5%
Gross Profit Margin 87.35% 84.51%
Selling, General & Admin $17.97M $16.66M
YoY Change 54.04% 59.92%
% of Gross Profit 144.9% 144.43%
Research & Development $6.765M $4.394M
YoY Change 100.21% 15.66%
% of Gross Profit 54.56% 38.1%
Depreciation & Amortization $182.0K $156.0K
YoY Change 40.0% 20.0%
% of Gross Profit 1.47% 1.35%
Operating Expenses $24.67M $21.05M
YoY Change 76.03% 48.09%
Operating Profit -$12.27M -$9.306M
YoY Change 110.99% 61.9%
Interest Expense -$1.122M $10.00K
YoY Change 18600.0% 66.67%
% of Operating Profit
Other Income/Expense, Net $6.342M $620.0K
YoY Change 984.1% 264.71%
Pretax Income -$7.053M -$8.701M
YoY Change 32.35% 55.82%
Income Tax $12.00K $11.00K
% Of Pretax Income
Net Earnings -$7.065M -$8.712M
YoY Change 31.98% 55.91%
Net Earnings / Revenue -49.77% -63.85%
Basic Earnings Per Share $0.34
Diluted Earnings Per Share -$0.28 $0.34
COMMON SHARES
Basic Shares Outstanding 25.55M 25.48M
Diluted Shares Outstanding 25.40M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $89.06M $60.12M
YoY Change 12.24% -28.58%
Cash & Equivalents $22.12M $50.85M
Short-Term Investments $66.94M $9.264M
Other Short-Term Assets $18.00K $26.00K
YoY Change -85.83% 52.94%
Inventory $5.596M $4.377M
Prepaid Expenses $1.376M $1.509M
Receivables $7.664M $5.875M
Other Receivables $30.00K $201.0K
Total Short-Term Assets $104.0M $73.93M
YoY Change 18.92% -19.4%
LONG-TERM ASSETS
Property, Plant & Equipment $1.877M $1.862M
YoY Change 56.42% 51.88%
Goodwill
YoY Change
Intangibles $487.0K $459.0K
YoY Change 4.73% 2.23%
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $355.0K $236.0K
YoY Change 190.98% -56.93%
Total Long-Term Assets $7.634M $7.087M
YoY Change -29.35% -13.7%
TOTAL ASSETS
Total Short-Term Assets $104.0M $73.93M
Total Long-Term Assets $7.634M $7.087M
Total Assets $111.6M $81.01M
YoY Change 13.61% -18.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.793M $3.000M
YoY Change 26.35% -3.78%
Accrued Expenses $7.972M $8.000M
YoY Change 10.19% 46.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.20M $11.84M
YoY Change 23.44% 24.42%
LONG-TERM LIABILITIES
Long-Term Debt $39.81M $0.00
YoY Change
Other Long-Term Liabilities $9.573M $6.200M
YoY Change 238.15% 154.83%
Total Long-Term Liabilities $39.81M $6.200M
YoY Change 1306.29% 154.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.20M $11.84M
Total Long-Term Liabilities $39.81M $6.200M
Total Liabilities $61.89M $17.41M
YoY Change 377.3% 49.11%
SHAREHOLDERS EQUITY
Retained Earnings -$298.0M -$290.9M
YoY Change 13.47% 13.09%
Common Stock $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.06M $62.98M
YoY Change
Total Liabilities & Shareholders Equity $111.6M $81.01M
YoY Change 13.61% -18.93%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$7.065M -$8.712M
YoY Change 31.98% 55.91%
Depreciation, Depletion And Amortization $182.0K $156.0K
YoY Change 40.0% 20.0%
Cash From Operating Activities -$10.86M -$8.980M
YoY Change 216.09% 223.37%
INVESTING ACTIVITIES
Capital Expenditures $291.0K $510.0K
YoY Change 315.71% -590.38%
Acquisitions
YoY Change
Other Investing Activities -$57.01M $22.27M
YoY Change 1746.24% -370.76%
Cash From Investing Activities -$57.30M $21.76M
YoY Change 1714.53% -361.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 39.43M 600.0K
YoY Change 4286.43%
NET CHANGE
Cash From Operating Activities -10.86M -8.980M
Cash From Investing Activities -57.30M 21.76M
Cash From Financing Activities 39.43M 600.0K
Net Change In Cash -28.73M 13.38M
YoY Change 404.48% -220.48%
FREE CASH FLOW
Cash From Operating Activities -$10.86M -$8.980M
Capital Expenditures $291.0K $510.0K
Free Cash Flow -$11.15M -$9.490M
YoY Change 218.08% 255.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001762303
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q3 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39059
dei Entity Registrant Name
EntityRegistrantName
AVITA MEDICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1021707
dei Entity Address Address Line1
EntityAddressAddressLine1
28159 Avenue Stanford
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 220
dei Entity Address City Or Town
EntityAddressCityOrTown
Valencia
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91355
dei City Area Code
CityAreaCode
(661)
dei Local Phone Number
LocalPhoneNumber
367-9170
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
RCEL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25550694
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50854000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18164000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9264000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
61178000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5875000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3515000
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
201000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
898000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3356000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1578000
CY2023Q3 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
4377000
CY2022Q4 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
2125000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
73927000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
87458000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
6930000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1862000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1200000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2607000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
851000
CY2023Q3 rcel Corporate Owned Life Insurance Asset
CorporateOwnedLifeInsuranceAsset
1923000
CY2022Q4 rcel Corporate Owned Life Insurance Asset
CorporateOwnedLifeInsuranceAsset
1238000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
459000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
465000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
236000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
122000
CY2023Q3 us-gaap Assets
Assets
81014000
CY2022Q4 us-gaap Assets
Assets
98264000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3019000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3002000
CY2023Q3 rcel Accrued Wages And Fringe Benefits
AccruedWagesAndFringeBenefits
7143000
CY2022Q4 rcel Accrued Wages And Fringe Benefits
AccruedWagesAndFringeBenefits
6623000
CY2023Q3 rcel Non Qualified Deferred Compensation Plan Liability Current
NonQualifiedDeferredCompensationPlanLiabilityCurrent
333000
CY2022Q4 rcel Non Qualified Deferred Compensation Plan Liability Current
NonQualifiedDeferredCompensationPlanLiabilityCurrent
78000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1341000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
990000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11836000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10693000
CY2023Q3 rcel Non Qualified Deferred Compensation Plan Liability
NonQualifiedDeferredCompensationPlanLiability
3361000
CY2022Q4 rcel Non Qualified Deferred Compensation Plan Liability
NonQualifiedDeferredCompensationPlanLiability
1270000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
365000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
698000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1845000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
306000
CY2023Q3 us-gaap Liabilities
Liabilities
17407000
CY2022Q4 us-gaap Liabilities
Liabilities
12967000
CY2023Q3 rcel Non Qualified Deferred Compensation Plan Share Awards
NonQualifiedDeferredCompensationPlanShareAwards
629000
CY2022Q4 rcel Non Qualified Deferred Compensation Plan Share Awards
NonQualifiedDeferredCompensationPlanShareAwards
557000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25550694
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25550694
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25208436
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25208436
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 rcel Common Stock Held By Non Qualified Deferred Compensation Plan
CommonStockHeldByNonQualifiedDeferredCompensationPlan
-1290000
CY2022Q4 rcel Common Stock Held By Non Qualified Deferred Compensation Plan
CommonStockHeldByNonQualifiedDeferredCompensationPlan
-127000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
347192000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
339825000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7977000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7627000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-290904000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-262588000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
62978000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84740000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81014000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98264000
CY2023Q3 us-gaap Revenues
Revenues
13645000
CY2022Q3 us-gaap Revenues
Revenues
9092000
us-gaap Revenues
Revenues
35948000
us-gaap Revenues
Revenues
24966000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
2113000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
1530000
us-gaap Cost Of Revenue
CostOfRevenue
5984000
us-gaap Cost Of Revenue
CostOfRevenue
4694000
CY2023Q3 us-gaap Gross Profit
GrossProfit
11532000
CY2022Q3 us-gaap Gross Profit
GrossProfit
7562000
us-gaap Gross Profit
GrossProfit
29964000
us-gaap Gross Profit
GrossProfit
20272000
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
212000
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
904000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1369000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2189000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10532000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5411000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27075000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15571000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6124000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5004000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20584000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18009000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4394000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3799000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14056000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10478000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
21050000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
14214000
us-gaap Operating Expenses
OperatingExpenses
61715000
us-gaap Operating Expenses
OperatingExpenses
44058000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9306000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5748000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30382000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21597000
CY2023Q3 us-gaap Interest Expense
InterestExpense
10000
CY2022Q3 us-gaap Interest Expense
InterestExpense
6000
us-gaap Interest Expense
InterestExpense
21000
us-gaap Interest Expense
InterestExpense
10000
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
615000
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
170000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2141000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
307000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8701000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5584000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28262000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21300000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8712000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5588000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
us-gaap Net Income Loss
NetIncomeLoss
-21312000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25401754
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25401754
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25006995
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25006995
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25281920
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25281920
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24972331
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24972331
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8712000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5588000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
us-gaap Net Income Loss
NetIncomeLoss
-21312000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-47000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-96000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-57000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-188000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
65000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-90000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
407000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-522000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8694000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5774000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27966000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22022000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
68647000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8712000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2367000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
110000
CY2023Q3 rcel Distribution Of Company Common Stock Held By The Nqdc Plan
DistributionOfCompanyCommonStockHeldByTheNQDCPlan
522000
CY2023Q3 rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
26000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
18000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
62978000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
92560000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5588000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1229000
CY2022Q3 rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
-29000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-186000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
87986000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84740000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5738000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
942000
rcel Distribution Of Company Common Stock Held By The Nqdc Plan
DistributionOfCompanyCommonStockHeldByTheNQDCPlan
522000
rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
-998000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
350000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
62978000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
104624000
us-gaap Net Income Loss
NetIncomeLoss
-21312000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5495000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
rcel Change In Classification Of Deferred Compensation Share Awards
ChangeInClassificationOfDeferredCompensationShareAwards
-192000
rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
80000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-710000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
87986000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
us-gaap Net Income Loss
NetIncomeLoss
-21312000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
445000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
438000
us-gaap Share Based Compensation
ShareBasedCompensation
6213000
us-gaap Share Based Compensation
ShareBasedCompensation
5782000
rcel Non Cash Lease Expense
NonCashLeaseExpense
531000
rcel Non Cash Lease Expense
NonCashLeaseExpense
515000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-83000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3000
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
17000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
4000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
23000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
121000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-149000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-284000
rcel Estimated Deferred Costs
EstimatedDeferredCosts
-147000
rcel Estimated Deferred Costs
EstimatedDeferredCosts
-12000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
255000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
253000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
113000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
10000
rcel Amortization Of Premium Of Marketable Securities
AmortizationOfPremiumOfMarketableSecurities
-794000
rcel Amortization Of Premium Of Marketable Securities
AmortizationOfPremiumOfMarketableSecurities
-12000
rcel Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan
NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan
-899000
rcel Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan
NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan
5000
rcel Increase Decrease In Trade And Other Receivables
IncreaseDecreaseInTradeAndOtherReceivables
-2473000
rcel Increase Decrease In Trade And Other Receivables
IncreaseDecreaseInTradeAndOtherReceivables
-449000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-697000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
484000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2057000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-168000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2405000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
119000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-571000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-531000
rcel Increase Decrease In Corporate Owned Life Insurance Asset
IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset
643000
rcel Increase Decrease In Corporate Owned Life Insurance Asset
IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset
840000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
114000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
163000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-70000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
433000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
524000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-570000
rcel Increase Decrease In Current Non Qualified Deferred Compensation Liability
IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability
-651000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
345000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
511000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
1174000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
829000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-333000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-212000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-50000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27148000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15654000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7633000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
59408000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2372000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
65289000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
43669000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1085000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
382000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
32000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
53000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58911000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16174000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
942000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
942000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-15000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-70000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32690000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31897000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18164000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55712000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50854000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23815000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
44000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
17000
us-gaap Interest Paid Net
InterestPaidNet
21000
us-gaap Interest Paid Net
InterestPaidNet
10000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
114000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification of prior year presentation</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain prior year amounts within Other current liabilities have been reclassified to Current non-qualified deferred compensation liability, in the Consolidated Balance Sheets for consistency with current period presentation. These reclassifications had no effect on the reported results of operations or financial position.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain prior-year amounts included in Note 11 - Reporting Segment and Geographic Information have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the total Revenues. An adjustment was made to reclassify COSMOTEC sales from the United States to Japan.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the accompanying Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts (including doubtful accounts, carrying value of long-lived assets, the useful lives of long-lived assets, accounting for marketable securities, income taxes, stock-based compensation, estimated credit losses, and the stand-alone selling price for the Biomedical Advanced Research and Development Authority (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">"BARDA"</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) contract) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 rcel Cash At Deposit Institutions
CashAtDepositInstitutions
4400000
CY2022Q4 rcel Cash At Deposit Institutions
CashAtDepositInstitutions
4100000
CY2023Q3 rcel Cash In Foreign Institutions
CashInForeignInstitutions
660000
CY2022Q4 rcel Cash In Foreign Institutions
CashInForeignInstitutions
737000
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
46400000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14100000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables and other receivables. As of September 30, 2023 and December 31, 2022, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits and subject to the risk of bank failure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> single commercial customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net accounts receivable. As of December 31, 2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> commercial customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total net accounts receivable. For the three-months and nine-months ended September 30, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> single customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenues.</span></p>
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
9284000
CY2023Q3 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
3000
CY2023Q3 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
23000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9264000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
61601000
CY2022Q4 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
1000
CY2022Q4 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
424000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
61178000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
6933000
CY2022Q4 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
7000
CY2022Q4 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
10000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
6930000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
260000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
194000
us-gaap Operating Lease Cost
OperatingLeaseCost
655000
us-gaap Operating Lease Cost
OperatingLeaseCost
582000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
28000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
318000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
190000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3215000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
466000
us-gaap Debt Securities Trading Unrealized Gain
DebtSecuritiesTradingUnrealizedGain
3000
us-gaap Debt Securities Trading Unrealized Loss
DebtSecuritiesTradingUnrealizedLoss
23000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-20000
CY2022 us-gaap Debt Securities Trading Unrealized Gain
DebtSecuritiesTradingUnrealizedGain
8000
CY2022 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-434000
CY2022 us-gaap Debt Securities Trading Unrealized Loss
DebtSecuritiesTradingUnrealizedLoss
426000
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2400000
CY2023Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2400000
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
17000
CY2023Q3 us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
17000
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
CY2022Q3 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
469000
CY2022Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
698000
CY2023Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
469000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
698000
CY2022Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000
CY2023Q1 rcel Increase In Operating Lease Rou Assets And Operating Lease Liabilities
IncreaseInOperatingLeaseRouAssetsAndOperatingLeaseLiabilities
1100000
CY2023Q2 rcel Increase In Operating Lease Rou Assets And Operating Lease Liabilities
IncreaseInOperatingLeaseRouAssetsAndOperatingLeaseLiabilities
1100000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2749000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
13000
us-gaap Variable Lease Cost
VariableLeaseCost
43000
us-gaap Variable Lease Cost
VariableLeaseCost
38000
CY2023Q3 us-gaap Lease Cost
LeaseCost
288000
CY2022Q3 us-gaap Lease Cost
LeaseCost
207000
us-gaap Lease Cost
LeaseCost
698000
us-gaap Lease Cost
LeaseCost
620000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
146000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
201000
us-gaap Operating Lease Payments
OperatingLeasePayments
556000
us-gaap Operating Lease Payments
OperatingLeasePayments
598000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2607000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
851000
CY2023Q3 rcel Right Of Use Assets
RightOfUseAssets
2607000
CY2022Q4 rcel Right Of Use Assets
RightOfUseAssets
851000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
904000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
612000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1845000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
306000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2749000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
918000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M3D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M8D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0868
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0671
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
257000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1028000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
738000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
684000
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2875000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1131000
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
661000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
384000
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
841000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
610000
CY2023Q3 us-gaap Inventory Net
InventoryNet
4377000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2125000
CY2023Q3 rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-81000
CY2022Q3 rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-125000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-149000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-284000
CY2023Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
578000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
119000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
459000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
558000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
93000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
465000
CY2023Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
4000
CY2022Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
26000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
50000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
9000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
35000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
35000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
35000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
35000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
34000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
222000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
405000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2257000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2152000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1862000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1200000
CY2023Q3 us-gaap Depreciation
Depreciation
156000
CY2022Q3 us-gaap Depreciation
Depreciation
130000
us-gaap Depreciation
Depreciation
419000
us-gaap Depreciation
Depreciation
388000
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
80000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
83000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1509000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
921000
CY2023Q3 rcel Investment Receivable
InvestmentReceivable
1500000
CY2023Q3 rcel Lease Deposits Current
LeaseDepositsCurrent
37000
CY2022Q4 rcel Lease Deposits Current
LeaseDepositsCurrent
110000
CY2023Q3 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
228000
CY2022Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
168000
CY2023Q3 rcel Contract Costs Current
ContractCostsCurrent
56000
CY2022Q4 rcel Contract Costs Current
ContractCostsCurrent
252000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
26000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
127000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3356000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1578000
CY2023Q3 us-gaap Deposit Assets
DepositAssets
151000
CY2022Q4 us-gaap Deposit Assets
DepositAssets
25000
CY2023Q3 rcel Other Long Term Assets Long Term Prepaids
OtherLongTermAssetsLongTermPrepaids
85000
CY2022Q4 rcel Other Long Term Assets Long Term Prepaids
OtherLongTermAssetsLongTermPrepaids
97000
CY2023Q3 rcel Other Long Term Assets
OtherLongTermAssets
236000
CY2022Q4 rcel Other Long Term Assets
OtherLongTermAssets
122000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
904000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
612000
CY2023Q3 rcel Barda Deferred Costs
BARDADeferredCosts
47000
CY2022Q4 rcel Barda Deferred Costs
BARDADeferredCosts
194000
CY2023Q3 rcel Barda Deferred Revenue
BARDADeferredRevenue
104000
CY2023Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
286000
CY2022Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
184000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1341000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
990000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q3 us-gaap Revenues
Revenues
13645000
CY2022Q3 us-gaap Revenues
Revenues
9092000
us-gaap Revenues
Revenues
35948000
us-gaap Revenues
Revenues
24966000
CY2023Q3 us-gaap Revenues
Revenues
13645000
CY2022Q3 us-gaap Revenues
Revenues
9092000
us-gaap Revenues
Revenues
35948000
us-gaap Revenues
Revenues
24966000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
2113000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
1530000
us-gaap Cost Of Revenue
CostOfRevenue
5984000
us-gaap Cost Of Revenue
CostOfRevenue
4694000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25550694
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25550694
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25208436
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25208436
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 rcel Share Based Compensation Expense Related To Equity
ShareBasedCompensationExpenseRelatedToEquity
2400000
CY2022Q3 rcel Share Based Compensation Expense Related To Equity
ShareBasedCompensationExpenseRelatedToEquity
1400000
rcel Share Based Compensation Expense Related To Equity
ShareBasedCompensationExpenseRelatedToEquity
6200000
rcel Share Based Compensation Expense Related To Equity
ShareBasedCompensationExpenseRelatedToEquity
5800000
CY2023Q3 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2022Q3 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2430000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1436000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6213000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5782000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2235446
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
919193
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
163750
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
240285
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
65921
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2684683
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1130952
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
460518
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
57798
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
178508
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
47536
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
292272
CY2023Q2 rcel Employee Stock Purchases Plan Effective Date
EmployeeStockPurchasesPlanEffectiveDate
2023-07-01
CY2023Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
1000000
CY2023Q3 rcel Employee Stock Purchase Plan Accrued Payroll Contributions
EmployeeStockPurchasePlanAccruedPayrollContributions
410000
CY2022Q4 rcel Employee Stock Purchase Plan Accrued Payroll Contributions
EmployeeStockPurchasePlanAccruedPayrollContributions
0
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8712000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5588000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
us-gaap Net Income Loss
NetIncomeLoss
-21312000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25402000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25402000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25007000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25007000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25282000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25282000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24972000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24972000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
117909
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
263000
CY2022Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
312000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
934000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
783000
CY2023Q3 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
3700000
CY2022Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
1300000
CY2023Q3 rcel Payout Of Deferred Compensation Liability
PayoutOfDeferredCompensationLiability
753000
us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
81052
rcel Deferred Compensation Arrangement With Individual Shares Vested
DeferredCompensationArrangementWithIndividualSharesVested
117909
rcel Deferred Compensation Arrangement With Individual Vested Redemption Value
DeferredCompensationArrangementWithIndividualVestedRedemptionValue
1300000
CY2022 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
253048
CY2022 rcel Deferred Compensation Arrangement With Individual Shares Vested
DeferredCompensationArrangementWithIndividualSharesVested
17927
CY2022 rcel Deferred Compensation Arrangement With Individual Vested Redemption Value
DeferredCompensationArrangementWithIndividualVestedRedemptionValue
127000

Files In Submission

Name View Source Status
rcel-20230930_cal.xml Edgar Link unprocessable
0000950170-23-062024-index-headers.html Edgar Link pending
0000950170-23-062024-index.html Edgar Link pending
0000950170-23-062024.txt Edgar Link pending
0000950170-23-062024-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img178726714_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rcel-20230930.htm Edgar Link pending
rcel-20230930.xsd Edgar Link pending
rcel-ex31_1.htm Edgar Link pending
rcel-ex31_2.htm Edgar Link pending
rcel-ex32.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rcel-20230930_def.xml Edgar Link unprocessable
rcel-20230930_lab.xml Edgar Link unprocessable
rcel-20230930_pre.xml Edgar Link unprocessable
rcel-20230930_htm.xml Edgar Link completed